Purine containing carbonucleoside phosphonate analogues as novel chemotype for Plasmodium falciparum Inhibition

Eur J Med Chem. 2023 Oct 5:258:115581. doi: 10.1016/j.ejmech.2023.115581. Epub 2023 Jun 25.

Abstract

The nucleotidase ISN1 is a potential therapeutic target of the purine salvage pathway of the malaria parasite Plasmodium falciparum. We identified PfISN1 ligands by in silico screening of a small library of nucleos(t)ide analogues and by thermal shift assays. Starting from a racemic cyclopentyl carbocyclic phosphonate scaffold, we explored the diversity on the nucleobase moiety and also proposed a convenient synthetic pathway to access the pure enantiomers of our initial hit (compound (±)-2). 2,6-Disubstituted purine containing derivatives such as compounds 1, (±)-7e and β-L-(+)-2 showed the most potent inhibition of the parasite in vitro, with low micromolar IC50 values. These results are remarkable considering the anionic nature of nucleotide analogues, which are known to lack activity in cell culture experiments due to their scarce capacity to cross cell membranes. For the first time, we report the antimalarial activity of a carbocyclic methylphosphonate nucleoside with an L-like configuration.

Keywords: Carbonucleosides; Malaria; Nucleotidase; Nucleotides; Plasmodium falciparum; Purine salvage pathway.

MeSH terms

  • Antimalarials* / metabolism
  • Antimalarials* / pharmacology
  • Nucleosides
  • Organophosphonates* / pharmacology
  • Plasmodium falciparum / metabolism
  • Purines / metabolism

Substances

  • Organophosphonates
  • Antimalarials
  • Nucleosides
  • Purines